Poland· PL-100230910

Ruconest

A conestat alfa product containing conestatum alfa, registered in Poland by Pharming Group N.V.. The same ATC class is registered in 11 of our 19 countries.

ATC B06AC04

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedRuconestATCB06AC04REGISTER NO.PL-100230910PACKS LISTED3CHECKEDSeptember 27, 2026

Where it is registered

Conestat alfa is registered in 11 of 19 countries.

Countries holding a registration under ATC B06AC04 (conestat alfa), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose

Conestat alfa · ATC B06AC04

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Conestatum alfa
Manufacturer
Pharming Group N.V.
Country
Poland (PL)
ATC code
B06AC04
ATC class
Conestat alfa
Defined daily dose
3.5 TSD, E
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909990796090
  • gtin
    08718309680008
  • gtin
    08718309680015

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

47 interactions on record for conestat alfa.

Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Conestat alfa · interactions on record

47 records

  • 5 severe
  • 42 moderate

Most severe, free to view

  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • ThalidomideL04AX02severe
  • LenalidomideL04AX04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ef2a2145-0be0-404e-b22c-355df7af0ba0
GET /v1/drugs/ef2a2145-0be0-404e-b22c-355df7af0ba0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania roztworu do wstrzykiwań",
  "source": "urpl",
  "strength": "2100 j.m.",
  "packaging": "05909990796090 ¦ Rpz ¦ Skasowane ¦ EU/1/10/641/001 ¦ 57784\n1 fiol.  proszku\n08718309680008 ¦ Rpz ¦ EU/1/10/641/001 ¦ 134808\n1 fiol.  proszku\n¦ UR/Z/4c/025/23 - 08718309680015",
  "substance": "Conestatum alfa 2100 j.m.",
  "common_name": "Conestatum alfa",
  "pl_product_id": "100230910",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about conestat alfa.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.